Pharmatek Gains DEA Approval

Pharmatek Laboratories has been approved by the U.S. Drug Enforcement Agency (DEA) for the analysis of Schedules I through V controlled substances, adding to its existing license to develop and manufacture drug products containing Schedules IV and V controlled substances.

“Receipt of this additional registration from the DEA demonstrates that we meet the Agency’s stringent requirements, and further validates our facility design, security systems, and procedures for analysis, handling, storage and disposal of controlled substances,” said Jeffrey Bibbs, Ph.D., chief executive officer and chief scientific officer at Pharmatek. ”This registration allows us to perform analytical and stability testing for all controlled-substance drug products within both our non-potent and highly-potent GMP facilities.”